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Background: Nonadherence to medication and incorrect use of inhalers represent significant 
barriers to optimal disease management of patients with chronic obstructive pulmonary disease 
(COPD). Thus, health care professionals (HCPs) play a critical role in educating their patients 
on appropriate inhaler use and in ensuring medication adherence. However, many patients do 
not receive appropriate inhaler training or have not had their inhaler technique checked.
Methods: The Real-life Experience and Accuracy of inhaLer use (REAL) survey was a 
computer-assisted, telephonic survey consisting of 23 questions gathering real-world informa-
tion on correct inhaler use, inhalation technique, device attributes, adherence, dosing accuracy, 
training, correct device use, ease of use, and factors that influence patient adherence in com-
mercially available inhalers delivering COPD maintenance therapy. All results are based on 
patient-reported data.
Results: The survey was conducted between January 4, 2016 and February 2, 2016. A total 
of 764 patients using various inhalers (Breezhaler® =186; Ellipta® =191; Genuair® =194; 
Respimat® =201) with mild to very severe COPD, with a mean ± SD age 56±9.8 years, com-
pleted the survey. Patient self-reported adherence was significantly lower in younger patients 
compared to older patients (p=0.020). Eighty-three percent of patients indicated that a demon-
stration (in-person) was “very helpful” versus 58% for video. Patient preferences for training 
methods were as follows: demonstration of inhaler use (83%), video (58%), instructions for 
use (51%), and leaflet (34%). Twenty-nine percent of patients had not been checked to see if 
they were using their device correctly by a HCP within the last two years. Patients who were 
checked were significantly more adherent than unchecked patients (p=0.020). The majority of 
the patients using Breezhaler reported either being very confident or confident of having taken a 
full dose, which was higher than those using Genuair, Ellipta (α=0.05), and Respimat (α=0.05). 
Treatment adherence in the last 30 days was highest with Breezhaler followed by Respimat, 
Ellipta, and Genuair.
Conclusion: The REAL survey identified attributes that influenced patient adherence and 
optimal inhaler use. Predictive attributes that influence patient adherence which HCPs should 
be aware of include age and disease severity. Modifiable attributes which the HCP can influ-
ence include correct inhaler use training, choice of training methods, checking patient inhaler 
technique at subsequent visits, and device selection. Inhalers are integral in the effective man-
agement of patients with COPD; it is therefore important that patients use the inhaler correctly 
and have full confidence in the dosage.
Keywords: chronic obstructive pulmonary disease, survey, inhaler use, adherence, dose con-
fidence, double dosing
Background
Inhaled therapy remains the cornerstone of chronic obstructive pulmonary disease 
(COPD) therapy. Inhaler devices facilitate the rapid delivery of small doses of drug 
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to the lungs to achieve high local concentrations at the 
targeted site, thereby reducing the risk of adverse effects as 
compared with systemic therapy.1 Effective inhaled thera-
pies for the treatment of COPD include bronchodilators and 
corticosteroids, most commonly delivered using pressurized 
metered-dose inhalers and dry powder inhalers.1,2 Effective 
treatment may be influenced by choice of inhaler device as 
specific device attributes may impact a patient’s satisfaction 
and adherence with therapy.3,4 Due to the chronic nature 
of COPD, long-term self-administration of medications is 
paramount for preventing disease progression. Adherence 
is the extent to which health behavior reflects a health plan 
constructed and agreed to by the patient as a partner with 
a clinician in health care decision-making.5 Adherence to 
medication is defined as successful initiation, implementa-
tion, and persistence to treatment and is fundamental in 
optimal disease management.6,7 Correct inhaler technique 
ensures that a full dose is received. Between 28% and 68% 
of patients use their inhalers incorrectly,8 which may result 
in ineffective management of COPD.9
There is increasing evidence that suggests correct inhaler 
technique is fundamental for effective therapy and that inhaler 
device type and mastery play important roles in improving 
adherence, clinical outcomes, health-related quality of life, 
and use of health care resources in patients with asthma and/or 
COPD.10–12 A recently published study showed critical errors 
are associated with COPD exacerbations, and critical errors 
are more common with non-breath-actuated inhalers.13 Poor 
inhaler technique, however, can significantly reduce effective 
delivery of the respirable fraction of the emitted dose that 
reaches the lungs.10 Studies have shown that many patients are 
not confident that they are using their inhaler correctly.9 Up 
to 94% of patients have demonstrated incorrect inhaler tech-
nique in clinical studies with either conventional pressurized 
metered-dose inhalers or dry powder inhalers.1
Unfortunately, a large proportion of patients also lack 
effective training from health care professionals (HCPs) on 
proper use of an inhaler device, with evidence suggesting 
that 39%–67% of HCPs do not train their patients on the 
correct use of their inhalers.14 Additionally, few patients are 
systematically checked at subsequent visits after the first 
prescription of an inhaler,15 despite the Global Initiative for 
Chronic Obstructive Lung Disease guidelines suggesting that 
physicians regularly assess patients for correct device use.16
HCPs cite patient satisfaction and ease of use as one of the 
most important attributes when selecting an inhaler device for 
patients,17 and these attributes can also affect treatment adher-
ence and effectiveness.14 In fact, treatment adherence has been 
shown to be modestly associated with inhaler satisfaction, 
better health status, and less frequent COPD exacerbations, 
although other factors are also likely to be involved.18 While 
patient satisfaction is important, correct inhaler technique is 
crucial as it can impact treatment outcomes.17
The Real-life Experience and Accuracy of inhaLer use 
(REAL) survey was a computer-assisted, telephonic survey 
conducted in patients with COPD to gather real-world infor-
mation on inhaler use, including information on the level of 
device training provided to the patients through to correct 
device use (adherence, correct dosing) and ease of use.
The objective of the REAL survey was to evaluate real-
world information on device training and factors that influence 
patient adherence in commercially available inhalers deliver-
ing COPD maintenance therapy via the Breezhaler® (Novartis 
AG, Basel, Switzerland), Ellipta® (GlaxoSmithKline, London, 
UK), Genuair® (Almirall, Barcelona, Spain), or Respimat® 
(Boehringer Ingelheim Pharma GmbH, Ingelheim, Germany) 
devices. The REAL survey results should serve as a guide 
to support good treatment practice for HCPs, help to further 
understand factors that promote adherence to medication, and 
enhance effective management of COPD.
Methods
The REAL survey was a 20-minute computer-assisted, tel-
ephonic survey consisting of 23 questions including (Table S1) 
16 closed-ended questions, 6 closed-ended questions where 
respondents were asked to explain an answer, and 1 open-ended 
question. The questions were derived from the Inhaler technique 
assessment initiative Helping Asthma in Real-life Patients 
and Optimum Patient Care COPD review questionnaires. The 
authors as a committee developed the REAL survey based on 
aforementioned questionnaires following a process of pretesting 
and expert review. Patients from 9 countries, Brazil, Canada, 
France, Germany, Italy, Japan, the Netherlands, UK, and USA, 
were surveyed. To ensure a representative global sample, 
patients on multiple continents were included in the study. A 
telephonic survey was selected as to ensure no limitations due 
to access or ability to use other technologies. The survey data 
were not weighted. The survey was conducted between January 
4, 2016 and February 2, 2016. This was a noninterventional 
market research study, and ethics approval was not required 
in accordance with the European Pharmaceutical market 
Research Association (ephmra.org). All patients provided writ-
ten informed consent at the beginning of recruitment and oral 
informed consent at the beginning of the telephone interview.
Patients included in the study were aged 40–75 years 
diagnosed with mild to very severe COPD by a general 
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physician or a pulmonologist, were using at least one of the 
4 devices (Breezhaler, Ellipta, Genuair, or Respimat) on a 
daily basis (maintenance therapy), and must have not par-
ticipated in any primary market research study on breathing 
problems within the 3 months prior to the survey. Patients 
were primarily selected upon physician referral, patient-
reported diagnosis, and experience with the inhaler devices 
included in this study. There was a limit on patient numbers 
for each device per country.
Patient-reported data on correct inhaler use (training and 
checks for correct use), inhalation technique, and device 
attributes (ease of use and confidence of inhaling full dose), 
and adherence and dosing accuracy data were collected. Key 
assessments used in the REAL survey are shown in Table 1. 
Demonstration of patient training was either in-person 
training by a HCP or by a virtual video presentation. All 
adverse events in relation to usage of Novartis’ Breezhaler 
device were reported within 24 hours to the respective 
country-specific Novartis drug safety departments (data on 
file). Significance testing was conducted using a χ2 test for 
comparisons of proportions applying a z-test. Significance 
levels were set at α,0.05.
Results
A total of 764 patients (Breezhaler =186; Ellipta =191; Genu-
air =194; Respimat =201) with mild to very severe COPD, 
with a mean ± SD age 56±9.8 years, completed the survey; 
51% and 49% of patients were male and female, respectively. 
The majority of patients (55%) reported moderate COPD 
severity with a mean time since diagnosis of 4.7±5.2 years; 
68% of patients were diagnosed by a pulmonologist.
Patient demographics are shown in Table 2. No sig-
nificant differences were observed between devices and 
disease severity. The majority of patients had used the device 
for more than a year (Figure 1). There was no significant 
difference in length of use between devices.
The patient population for the older than 65 years group 
was smaller (N=163) than the 65 years and under (N=601) 
group. Younger patients were significantly more likely to 
have mild and moderate disease compared to older patients 
(Table 3). Patient COPD severity tended to increase from 
each increasing age group.
Patient self-reported adherence is shown in Table 4. 
Patient adherence was significantly lower in patients 
aged 65 years compared to patients aged 65 years 
(p=0.020). No significant difference in adherence was 
observed between genders, disease severity or time since 
diagnosis. No significant difference in confidence of inhaling 
full dose was observed for gender, age, disease severity, or 
time since diagnosis.
Influence of training is shown in Table 5. Trained respon-
dents were significantly more confident that the correct dose 
was taken. Approximately 30% of all patients reported not 
having received any training on inhaler use. Of the 70% of 
patients that received training, the most common patient pref-
erence for training was demonstration of inhaler use (83%) 
followed by video (58%), instructions for use (51%), and 
leaflet (34%) (Figure 2). Adherent patients were significantly 
more often trained with a demonstration than nonadherent 
patients (p=0.037). Adherent patients were significantly 
more often trained by a pulmonologist than nonadherent 
patients (p=0.001).
Training was mainly performed by pulmonologists 
(41.3%), pharmacists (20.2%), nurses (18.1%), general phy-
sicians (12.0%), or others (8.4%) (Figure S1). Pulmonologists 
who diagnosed a patient as having COPD were most likely 
to train the patients themselves, whereas general physicians 
who diagnose the patient were more likely to delegate train-
ing to pulmonologists, pharmacists, and nurses.
Figure 2 shows that 83% of patients indicated demonstration 
was “very helpful” versus 58% for video. Patient preferences 
Table 1 Key assessments used in the real survey
Question Variable
Confidence in taking 
a full dose
Very low confidence
Low confidence
Neither high nor low confidence
Confident
Very confident
Inhaling correct dose number of inhalations/puffs
self-reported 
adherence
Patients were considered fully adherent if 
they reported having taken their medication 
every day within the last 30 days
ease of use Very difficult
Somewhat difficult
Neither difficult nor easy
somewhat easy
Very easy
Did you ever receive 
any training on how 
to use the device?
Yes
If Yes, how did the patient receive training:
Leaflet
IFU
Video
Demonstration
Other
no
Training effectiveness 
(helpfulness of 
specific methods 
mentioned by 
patient)
Very unhelpful
somewhat unhelpful
neither helpful nor unhelpful
somewhat helpful
Very helpful
Abbreviations: IFU, instructions for use; real, real-life experience and accuracy 
of inhaler use.
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(Figure 2) for training methods were demonstration of inhaler 
use (83%) followed by video (58%), instructions for use 
(51%), and leaflet (34%).
Twenty-nine percent (29%) of patients had not been 
checked to see if they were using their device correctly within 
the last 2 years. Patients who were checked were significantly 
more adherent than unchecked patients (p=0.020). Patients 
who were checked for inhaler technique felt more confident 
that they received the full dose compared to those who 
were unchecked. Potential medication errors were identified 
as repeating dose (overdosing with Genuair and Ellipta) 
when not confident, or incorrect dosing (eg, underdosing 
??
??? ???
??
???
???
???
???
??? ???
???
??????
?? ??
???
??
?? ??
???
?? ???? ????
???
???
???
???
???
???
????????????????? ?????????????? ?????????????? ????? ?????????
??????????????????????????????????????????????????????????????????
Figure 1 length of use by device.
Table 2 Patient demographics
Inhaler Total Germany the Netherlands Brazil Japan France Italy UK USA Canada
Breezhaler®a n=186 37 17 36 17 27 22 15 0a 15
ellipta® n=191 19 10 28 12 26 24 22 25 25
genuair®b n=194 35 20 0b 17 0b 23 32 33 34
respimat® n=201 22 6 24 26 26 23 19 27 28
Total n=764c 110c 53 88 70c 77c 92 87c 85 102
Demographics
sex
Male 51% 50% 47% 24% 81% 47% 59% 61% 48% 50%
Female 49% 50% 53% 76% 19% 53% 41% 39% 52% 50%
age, years
Mean 56 60 57 48 56 57 55 56 55 57
40–49 31% 17% 21% 65% 36% 25% 33% 31% 28% 24%
50–59 33% 26% 38% 19% 24% 34% 39% 30% 44% 39%
60–69 26% 40% 36% 15% 33% 30% 20% 26% 20% 22%
70–75 10% 16% 6% 1% 7% 12% 9% 13% 8% 16%
severity of COPD
Mild 26% 13% 42% 24% 43% 17% 27% 36% 13% 29%
Moderate 55% 47% 51% 48% 53% 58% 52% 55% 71% 61%
severe 15% 26% 8% 25% 4% 21% 17% 9% 14% 8%
Very severe 4% 14% 0% 3% 0% 4% 3% 0% 2% 2%
Time since COPD diagnosis, years
Mean 4.7 7.3 4.2 3.6 5.0 4.9 5.0 4.8 3.4 3.4
COPD diagnosis by
general physician/
primary care physician
32% 15% 47% 26% 39% 16% 33% 37% 53% 37%
Pulmonologist 68% 85% 53% 74% 61% 84% 67% 63% 47% 63%
Notes: aThere were no Us Breezhaler patients included in the study as the therapy was not available at the time of the survey in the Us; bthere were no Brazil or France 
genuair patients included in the study as the therapy was not available at the time of the survey in Brazil or France; cTotal number of patients was lower than sum of patients 
by device as some patients were using multiple devices.
Abbreviation: COPD, chronic obstructive pulmonary disease.
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with Respimat). Checked patients also felt more confident 
that they received the full dose compared to those who were 
unchecked (Table 6).
Patient-reported inhaler treatment adherence in the last 
30 days was highest with Breezhaler followed by Respimat, 
Ellipta, and Genuair (Figure 3). Patient-reported inhaler 
treatment adherence was significantly higher with Bree-
zhaler (90%) versus Ellipta (65%) (p=0.001). Significantly 
more patients felt confident or very confident of having 
taken their full dose of medication with Breezhaler versus 
patients using Ellipta (p=0.001) or patients using Respimat 
(p=0.001) (Table 7). Ninety-three percent felt confident or 
very confident of having taken the full dose with Breezhaler, 
and this was more than any that reported for any other device 
(Table 7). Most patients reported being confident (34%–54%) 
or very confident (24%–59%) of having taken the full 
dose (Table 7). Of the patients who did not feel confident, 
more patients reported overdosing with Genuair, Ellipta, 
and Respimat (33.2%, 29.4%, and 21.4%, respectively). 
Only few patients reported overdosing using Breezhaler 
(4.4%) (Table 7). The majority of patients had correct dosing 
of their COPD medication (Figure 4).
Discussion
The REAL survey was a computer-assisted, telephonic 
survey in COPD patients which gathered real-world infor-
mation on correct inhaler use, inhalation technique, and 
device attributes, as well as adherence and dosing accuracy, 
training, correct device use, ease of use, and factors that influ-
ence patient adherence in commercially available inhalers 
delivering COPD maintenance therapy via the Breezhaler, 
Ellipta, Genuair, and Respimat devices.
Disease severity was similar across patients utilizing dif-
ferent devices. Severity of disease was significantly different 
with respect to age; older patients were more likely to have 
greater disease severity. Patients with mild disease were 
primarily younger, while those with severe to very severe 
disease were predominately older.
Patient-reported inhaler treatment adherence in the last 
30 days was highest with Breezhaler followed by Respimat, 
Ellipta, and Genuair. Adherence was lower in younger 
patients compared to older patients. This may be due to 
milder disease severity in younger patients. Patients with 
milder disease may not see the need to regularly take their 
prescribed medication as they may believe that their symp-
toms are not serious or their condition is controlled. Gender, 
disease severity, or time since diagnosis did not influence 
adherence. Patient-reported inhaler treatment adherence 
was highest with Breezhaler followed by Respimat, Ellipta, 
and Genuair.
Training is integral to effective device use and subsequent 
disease control. Misuse of inhalers has been linked to poor 
disease control.17 COPD guidelines recommend that inhaler 
training should be continually assessed at subsequent clinic 
visits. Where necessary, retraining should be provided.16 
The benefits of training were demonstrated in this study, 
where training with a demonstration was common among 
Table 3 Patient disease severity and age
  Age group
40–49 
years
n=236
50–59 
years
n=248
60–69 
years
n=202
70–75 
years
n=78
n % n % n % n %
severity Mild 81a 34 62 25 39 19 15 19
Moderate 126 53 152b 61 109 54 34 44
severe 27 11 30 12 43c 21 18d 23
Very severe 2 1 4 2 11 5 11e 14
Notes: ap=0.001 (comparison to 60–69 years); bp=0.006 (comparison to 70–75 years); 
cp=0.005 (comparison to 40–49 years); dp=0.011 (comparison to 40–49 years); 
ep=0.001 (comparison to 40–49 and 50–59 years).
Table 4 Patient adherence
Adherent
n=539
Nonadherent
n=225
p-value
n % n %
gender Male 276 51 117 52 p=0.841
Female 263 49 108 48
age 65 years 412 76 189 84 p=0.020
65 years 127 24 36 16
severity Mild 141 26 56 25 p=0.711
Moderate 288 53 133 59 p=0.150
severe 86 16 32 14 p=0.549
Very severe 24 4 4 2 p=0.073
Time since 
diagnosis
newly diagnosed 
(12 months)
81 15 45 20 p=0.091
long time diagnosis 
(12 months)
458 85 180 80
Table 5 Trained and untrained patient influencers
 Trained 
patients
n=535
Untrained 
patients
n=225
p-value
n % n %
adherence Compliant 356 67 181 80 p=0.001
noncompliant 179 33 44 20
Confidence 
that full dose 
has been taken
Low confidence 15 3 17 8 p=0.003
neutral 53 10 43 19 p=0.001
Confident 467 87 165 73 p=0.001
Correct dosing Correct dosing 448 84 180 80 p=0.215
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adherent patients. These patients were more often trained 
by a pulmonologist. General practitioners who diagnose the 
patient were more likely to delegate training to pulmonolo-
gists, pharmacists, and nurses. Gender, age, disease severity, 
or time since diagnosis were not factors that influenced cor-
rect dosing. However, trained patients were more confident 
that the correct dose was taken. When patients did not feel 
confident of having received the full dose, they reported 
having inhaled another dose at the same time or at a later time 
(overdosing). The majority of patients were more confident 
of having taken their full dose of medication with Breezhaler 
versus Ellipta, Genuair, or Respimat. Patients who were 
checked for correct device usage were more adherent than 
unchecked patients. These checked patients also felt more 
confident that they received the full dose. Evidence suggests 
that patients prefer inhalers that provide feedback on dose 
administration and find such devices easy to use (patients 
are more likely to adhere to the prescribed treatment when 
they use such an inhaler).17 Adherent patients were more 
compliant when their inhaler technique was checked com-
pared to unchecked patients. Inhaler use has been frequently 
reported as suboptimal.19 Drivers of adherence are paramount 
to COPD disease management. Inhalers are the key route of 
administration. Checking of inhaler use contributes toward 
optimal and correct inhaler use.
HCPs should be aware of predictive factors for patient 
adherence including patient age. Younger patients are 
significantly less compliant with milder disease severity. 
Patients should be trained to use their inhalers correctly by 
HCPs using effective training methods so as to achieve the 
full benefit of inhaled therapy. Correct inhaler technique 
should be assessed at subsequent follow-ups. HCPs should be 
aware that individual device attributes may influence patient 
adherence and confidence of dosage. Many patients with 
COPD achieve incomplete benefit from their treatment, due 
to inadequate device training or incorrect inhaler technique. 
Inhaler overuse and underuse are the most common forms 
of nonadherence. Overall, this leads to inhaler use errors and 
may negatively impact treatment adherence. This survey 
shows low incidence of training or monitoring (by HCPs) 
for correct inhaler use.
Devices that provide low confidence of having inhaled 
the full dose may result in underuse or overuse of medication, 
which may also impact efficacy and/or safety outcomes in 
patients. Thus, there is a need for enhancing the HCP–patient 
interaction through effective training programs. Considering 
that patients with COPD self-administer their medication, 
these insights should be considered for successful manage-
ment of COPD.
Limitations of the survey were that measures of patient 
adherence were based on patient report. Additionally, there 
may have been possible selection bias and recall bias. The 
survey was also not a randomized trial and reflected real-
world experience.
Table 6 Adherence and optimal inhaler use in checked and 
unchecked patients
  Checked 
patients
n=524
Unchecked 
patients
n=240
p-value
n % n %
adherence Compliant 383 73 156 65 p=0.020
noncompliant 141 27 84 35
Confidence 
that full dose 
has been taken
Low confidence
neutral
Confident
18
50
456
3
10
87
14
46
180
6
19
75
p=0.123
p=0.001
p=0.001
Correct dosing Correct dosing 426 81 205 85 p=0.165
???
??? ??
??
??? ??? ???
???
???
??? ???
???
??
???
???
???
???
???
???
???
???
???
?????? ??? ????? ?????????????
????????????????????????????? ???????????????? ????????????
Figure 2 Patient preferences for using different training methods.
Abbreviation: IFU, instructions for use.
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appropriate inhaler use in patients with COPD
Table 7 Patient-reported confidence of taking full and self-reported correct dose
Parameter Breezhaler® Ellipta® Genuair® Respimat®
Confident or very confident of having taken the full dose 93% 80% 84% 76%
“When you think you feel you have not had a full dose, what 
do you typically do? – I inhale another dose at the same time”
4% 25% 33% 15%
Patients taking correct dosea 97% 93% 91% 50%
Notes: aCorrect dose for Breezhaler and ellipta represents one puff per dose each day; for genuair, one puff per dose twice a day; for respimat, two puffs per dose each day.
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Figure 3 self-reported adherence with COPD medication in last 30 days.
Abbreviation: COPD, chronic obstructive pulmonary disease.
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Figure 4 Proportion of device correct dosing.
Conclusion
The results presented are of significant importance as device 
attributes that lead to confidence of full dose received 
may improve treatment adherence by reducing the risk of 
overdosing or underdosing drug administration in patients. 
Further investigation into the factors of medication errors 
is still required. Inhalers play a crucial role in the effective 
management of patients with COPD; it is therefore important 
that patients have full confidence in the use of their inhaler.
Acknowledgment
The authors thank Clarice Field (PhD) and Paul McKiernan 
(PhD) of Novartis for providing medical writing support, 
which was funded by Novartis AG, Basel, Switzerland, 
in accordance with Good Publication Practice (GPP3) 
guidelines (http://www.ismpp.org/gpp3). Pankaj Goyal 
and Joao Mendes, Novartis Pharma AG, Basel, contributed 
to the design and conceptualization of study. The survey 
was designed by PDD, London, United Kingdom, and GfK 
Switzerland AG, Basel, Switzerland. The survey was con-
ducted by GfK Switzerland AG, Basel, Switzerland, and 
sponsored by Novartis Pharma AG, Basel, Switzerland.
Disclosure
DLK, VB, and FSG are all employees of Novartis and have 
received no other funding. MG and SW are employees of 
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f C
hr
on
ic 
O
bs
tru
ct
ive
 P
ul
m
on
ar
y 
Di
se
as
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
9.
13
3.
14
8.
28
 o
n 
13
-M
ar
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of COPD
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journal
The International Journal of COPD is an international, peer-reviewed 
journal of therapeutics and pharmacology focusing on concise rapid 
reporting of clinical studies and reviews in COPD. Special focus is given 
to the pathophysiological processes underlying the disease, intervention 
programs, patient focused education, and self management protocols. 
This journal is indexed on PubMed Central, MedLine and CAS. The 
manuscript management system is completely online and includes a 
very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
International Journal of COPD 2018:13submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
702
Price et al
GfK Switzerland AG and have received no other funding. 
Professor David Price has board membership with Aerocrine, 
Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Mylan, 
Mundipharma, Napp, Novartis, and Teva Pharmaceuticals; 
consultancy agreements with Almirall, Amgen, AstraZeneca, 
Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Mylan, 
Mundipharma, Napp, Novartis, Pfizer, Teva Pharmaceuti-
cals, and Theravance; grants and unrestricted funding for 
investigator-initiated studies (conducted through Observa-
tional and Pragmatic Research Institute Pte Ltd) from Aero-
crine, AKL Research and Development Ltd, AstraZeneca, 
Boehringer Ingelheim, British Lung Foundation, Chiesi, 
Mylan, Mundipharma, Napp, Novartis, Pfizer, Respiratory 
Effectiveness Group, Teva Pharmaceuticals, Theravance, 
UK National Health Service, Zentiva; payment for lectures/
speaking engagements from Almirall, AstraZeneca, Boeh-
ringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Kyorin, 
Mylan, Merck, Mundipharma, Novartis, Pfizer, Skyepharma, 
and Teva Pharmaceuticals; payment for manuscript prepara-
tion from Mundipharma and Teva Pharmaceuticals; payment 
for the development of educational materials from Mundip-
harma and Novartis; payment for travel/accommodation/
meeting expenses from Aerocrine, AstraZeneca, Boehringer 
Ingelheim, Mundipharma, Napp, Novartis, and Teva Phar-
maceuticals; funding for patient enrolment or completion of 
research from Chiesi, Novartis, Teva Pharmaceuticals, and 
Zentiva; stock/stock options from AKL Research and Devel-
opment Ltd which produces phytopharmaceuticals; owns 74% 
of the social enterprise Optimum Patient Care Ltd (Australia, 
Singapore, and UK) and 74% of Observational and Pragmatic 
Research Institute Pte Ltd (Singapore); and is peer reviewer 
for grant committees of the Efficacy and Mechanism Evalu-
ation Programme, and Health Technology Assessment. The 
authors report no other conflicts of interest in this work.
References
1. Lavorini F. Inhaled drug delivery in the hands of the patient. J Aerosol 
Med Pulm Drug Deliv. 2014;27(6):414–418.
2. Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes 
of aerosol therapy: evidence-based guidelines: American College of 
Chest Physicians/American College of Asthma, Allergy, and Immunol-
ogy. Chest. 2005;127(1):335–371.
 3. Lavorini F, Fontana GA. Inhaler technique and patient’s prefer-
ence for dry powder inhaler devices. Expert Opin Drug Deliv. 2014; 
11(1):1–3.
 4. Anderson P. Patient preference for and satisfaction with inhaler devices. 
European Res Rev. 2005;14(96):109–116.
 5. Berger BA. Assessing and interviewing patients for meaningful behav-
ioral change: Part 1. Case Manager. 2004;15(5):46–50; quiz 51.
 6. Braido F, Chrystyn H, Baiardini I, et al. “Trying, But Failing” – the role 
of inhaler technique and mode of delivery in respiratory medication 
adherence. J Allergy Clin Immunol Pract. 2016;4(5):823–832.
 7. Vrijens B, Dima AL, Van Ganse E, et al. What we mean when we talk 
about adherence in respiratory medicine. J Allergy Clin Immunol Pract. 
2016;4(5):802–812.
 8. Fink JB, Rubin BK. Problems with inhaler use: a call for improved 
clinician and patient education. Respir Care. 2005;50(10):1360–1374; 
discussion 1374–1365.
 9. Lavorini F, Magnan A, Dubus JC, et al. Effect of incorrect use of dry 
powder inhalers on management of patients with asthma and COPD. 
Respir Med. 2008;102(4):593–604.
 10. Chrystyn H, Price DB, Molimard M, et al. Comparison of serious inhaler 
technique errors made by device-naive patients using three different 
dry powder inhalers: a randomised, crossover, open-label study. BMC 
Pulm Med. 2016;16:12.
 11. Bosnic-Anticevich S, Chrystyn H, Costello RW, et al. The use of mul-
tiple respiratory inhalers requiring different inhalation techniques has 
an adverse effect on COPD outcomes. Int J Chron Obstruct Pulmon 
Dis. 2017;12:59–71.
 12. Price DB, Roman-Rodriguez M, McQueen RB, et al. Inhaler errors in 
the CRITIKAL study: type, frequency, and association with asthma 
outcomes. J Allergy Clin Immunol Pract. 2017;5(4):1071–1081.
 13. Molimard M, Raherison C, Lignot S, et al. Chronic obstructive pul-
monary disease exacerbation and inhaler device handling: real-life 
assessment of 2935 patients. Eur Respir J. 2017;49(2). pii: 1601794.
 14. Miravitlles M, Montero-Caballero J, Richard F, et al. A cross-sectional 
study to assess inhalation device handling and patient satisfaction 
in COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:407–415.
 15. Bosnic-Anticevich SZ, Sinha H, So S, Reddel HK. Metered-dose 
inhaler technique: the effect of two educational interventions delivered 
in community pharmacy over time. J Asthma. 2010;47(3):251–256.
 16. Global Strategy for the Diagnosis, Management and Prevention 
of COPD, Global Initiative for Chronic Obstructive Lung Disease 
(GOLD); 2017. Available from: http://goldcopd.org. Accessed August 
6, 2017.
 17. Molimard M, Colthorpe P. Inhaler devices for chronic obstructive 
pulmonary disease: insights from patients and healthcare practitioners. 
J Aerosol Med Pulm Drug Deliv. 2015;28(3):219–228.
 18. Chrystyn H, Small M, Milligan G, Higgins V, Gil EG, Estruch J. Impact 
of patients’ satisfaction with their inhalers on treatment compliance and 
health status in COPD. Respir Med. 2014;108(2):358–365.
 19. Sanchis J, Gich I, Pedersen S; Aerosol Drug Management Improvement 
Team (ADMIT). Systematic review of errors in inhaler use: has patient 
technique improved over time? Chest. 2016;150(2):394–406.
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f C
hr
on
ic 
O
bs
tru
ct
ive
 P
ul
m
on
ar
y 
Di
se
as
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
9.
13
3.
14
8.
28
 o
n 
13
-M
ar
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
